ADAPY Adaptimmune Therapeutics PLC
Biological Products, (No Diagnostic Substances) · OTC · SEC CIK 1621227 · Fiscal year ends 12/31
Financial factors as of 2025-06-30 (2025Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY-54.0%
TTM net income YoY-134.1%
TTM EPS YoY-83.3%
Revenue 3-yr CAGR77.0%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-252.3%
Net margin-260.8%
FCF margin-294.5%
EBITDA margin-237.0%
Returns
ROE-1,341.1%
ROA-75.1%
ROIC (approx.)—
Asset turnover0.29x
Leverage & solvency
Liabilities / assets154.3%
Debt / equity—
Current ratio1.52x
Interest coverage-28.99x
Cash quality & payout
Operating cash flow / net income1.12x
Accruals ratio9.0%
Payout ratio—
Capex / revenue2.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 | FY20202020-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $178.03M | $60.28M | $27.15M | $6.15M | $3.96M |
| Cost of revenue | $70,000 | — | — | — | — |
| Gross profit | $177.96M | — | — | — | — |
| R&D expense | $149.06M | $126.51M | $127.73M | $111.09M | $91.57M |
| SG&A expense | $87.26M | $73.51M | $63.39M | $57.30M | $45.80M |
| Operating income | -$68.76M | -$139.74M | -$163.97M | -$162.25M | -$133.41M |
| Interest expense | $3.35M | — | — | — | — |
| Pretax income | -$67.24M | -$112.53M | -$162.96M | -$157.30M | -$129.93M |
| Income tax | $3.58M | $1.34M | $2.50M | $791,000 | $162,000 |
| Net income | -$70.81M | -$113.87M | -$165.46M | -$158.09M | -$130.09M |
| EBITDA | -$57.95M | -$130.29M | -$158.70M | -$156.62M | -$126.78M |
| EPS (basic) | -0.05 | -0.09 | -0.17 | -0.17 | -0.15 |
| EPS (diluted) | -0.05 | -0.09 | -0.17 | -0.17 | -0.15 |
| Weighted avg. shares (diluted) | 1.51B | 1.21B | 967.24M | 934.83M | 854.78M |
| Balance sheet | |||||
| Cash & equivalents | $91.14M | $147.02M | $109.60M | $151.67M | $61.48M |
| Short-term investments | $60.47M | $2.95M | $96.57M | $219.63M | $311.33M |
| Receivables | $1.45M | $821,000 | $7.43M | $752,000 | $139,000 |
| Inventory | $7.32M | — | — | — | — |
| Current assets | $188.17M | $207.55M | $255.37M | $415.46M | $398.15M |
| PP&E, net | $31.31M | $50.95M | $53.52M | $30.49M | $27.78M |
| Intangibles | $3.88M | $330,000 | $442,000 | $1.00M | $1.73M |
| Total assets | $245.96M | $282.62M | $328.92M | $469.55M | $451.14M |
| Current liabilities | $64.53M | $72.79M | $64.50M | $62.54M | $39.07M |
| Long-term debt | $50.24M | — | — | — | — |
| Total debt | $50.24M | — | — | — | — |
| Total liabilities | $234.11M | $243.10M | $247.04M | $263.58M | $109.92M |
| Shareholders' equity | $11.85M | $39.51M | $81.88M | $205.96M | $341.23M |
| Net debt | -$40.90M | — | — | — | — |
| Shares outstanding | 1.54B | 1.36B | 987.11M | 928.55M | 928.75M |
| Cash flow statement | |||||
| Operating cash flow | -$73.21M | -$140.88M | -$141.77M | $10.73M | -$53.59M |
| Capital expenditure | $886,000 | $4.68M | $29.50M | $8.57M | $2.34M |
| Free cash flow | -$74.09M | -$145.56M | -$171.26M | $2.15M | -$55.93M |
| Investing cash flow | -$58.95M | $176.54M | $89.14M | $75.80M | -$278.92M |
| Financing cash flow | $78.75M | $880,000 | $12.87M | $3.29M | $340.05M |
| Depreciation & amortization | $10.81M | $9.45M | $5.27M | $5.63M | $6.63M |
| Stock-based compensation | $12.05M | $11.77M | $18.24M | $20.63M | $10.41M |
Free plan shows the latest 5 periods; Pro shows all 11 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.